These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 15296757)

  • 1. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo.
    Liddament MT; Brown WL; Schumacher AJ; Harris RS
    Curr Biol; 2004 Aug; 14(15):1385-91. PubMed ID: 15296757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n.
    Refsland EW; Hultquist JF; Harris RS
    PLoS Pathog; 2012; 8(7):e1002800. PubMed ID: 22807680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
    Mangeat B; Turelli P; Caron G; Friedli M; Perrin L; Trono D
    Nature; 2003 Jul; 424(6944):99-103. PubMed ID: 12808466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The retroviral hypermutation specificity of APOBEC3F and APOBEC3G is governed by the C-terminal DNA cytosine deaminase domain.
    Haché G; Liddament MT; Harris RS
    J Biol Chem; 2005 Mar; 280(12):10920-4. PubMed ID: 15647250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G.
    Holmes RK; Koning FA; Bishop KN; Malim MH
    J Biol Chem; 2007 Jan; 282(4):2587-95. PubMed ID: 17121840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication.
    Zheng YH; Irwin D; Kurosu T; Tokunaga K; Sata T; Peterlin BM
    J Virol; 2004 Jun; 78(11):6073-6. PubMed ID: 15141007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
    Xu H; Svarovskaia ES; Barr R; Zhang Y; Khan MA; Strebel K; Pathak VK
    Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5652-7. PubMed ID: 15054139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible footprints of APOBEC3F and/or other APOBEC3 deaminases, but not APOBEC3G, on HIV-1 from patients with acute/early and chronic infections.
    Armitage AE; Deforche K; Welch JJ; Van Laethem K; Camacho R; Rambaut A; Iversen AK
    J Virol; 2014 Nov; 88(21):12882-94. PubMed ID: 25165112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates.
    Zennou V; Bieniasz PD
    Virology; 2006 May; 349(1):31-40. PubMed ID: 16460778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population level analysis of human immunodeficiency virus type 1 hypermutation and its relationship with APOBEC3G and vif genetic variation.
    Pace C; Keller J; Nolan D; James I; Gaudieri S; Moore C; Mallal S
    J Virol; 2006 Sep; 80(18):9259-69. PubMed ID: 16940537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.
    Zhang H; Yang B; Pomerantz RJ; Zhang C; Arunachalam SC; Gao L
    Nature; 2003 Jul; 424(6944):94-8. PubMed ID: 12808465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guanine-adenine bias: a general property of retroid viruses that is unrelated to host-induced hypermutation.
    Müller V; Bonhoeffer S
    Trends Genet; 2005 May; 21(5):264-8. PubMed ID: 15851060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human retroviral host restriction factors APOBEC3G and APOBEC3F localize to mRNA processing bodies.
    Wichroski MJ; Robb GB; Rana TM
    PLoS Pathog; 2006 May; 2(5):e41. PubMed ID: 16699599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical differentiation of APOBEC3F and APOBEC3G proteins associated with HIV-1 life cycle.
    Wang X; Dolan PT; Dang Y; Zheng YH
    J Biol Chem; 2007 Jan; 282(3):1585-94. PubMed ID: 17142455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of a yeast LTR retrotransposon by human APOBEC3 cytidine deaminases.
    Dutko JA; Schäfer A; Kenny AE; Cullen BR; Curcio MJ
    Curr Biol; 2005 Apr; 15(7):661-6. PubMed ID: 15823539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different mutagenic potential of HIV-1 restriction factors APOBEC3G and APOBEC3F is determined by distinct single-stranded DNA scanning mechanisms.
    Ara A; Love RP; Chelico L
    PLoS Pathog; 2014 Mar; 10(3):e1004024. PubMed ID: 24651717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.
    Luo K; Wang T; Liu B; Tian C; Xiao Z; Kappes J; Yu XF
    J Virol; 2007 Jul; 81(13):7238-48. PubMed ID: 17428847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities.
    Langlois MA; Beale RC; Conticello SG; Neuberger MS
    Nucleic Acids Res; 2005; 33(6):1913-23. PubMed ID: 15809227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
    Russell RA; Pathak VK
    J Virol; 2007 Aug; 81(15):8201-10. PubMed ID: 17522216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination.
    Bishop KN; Holmes RK; Malim MH
    J Virol; 2006 Sep; 80(17):8450-8. PubMed ID: 16912295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.